African Institute for Health and Development (AIHD)
Rapid assessment of community preparedness for LF MDA activities in the context of COVID-19
To assess community readiness to participate in LF activities (surveys, social mobilisation, MDA and evaluations) in the context of COVID-19 in Kenya.
Understanding the factors that motivate and sustain community drug distributors in the changing context of NTD control and elimination
How do we motivate community drug distributors (CDDs)?
Rapid assessment of community preparedness for LF MDA activities in the context of COVID-19
To assess community readiness to participate in LF activities (surveys, social mobilisation, MDA and evaluations) in the context of COVID-19 in Kenya.
Equitable access to Mass Drug Administration for trachoma elimination: an ethnographic study to understand factors associated with low coverage in Kenya and Tanzania
Main objectives are firstly to identify and understand better the factors behind low and unequal MDA coverage and compliance in trachoma endemic areas in Tanzania and Kenya with nomadic populations, secondly to prioritize factors in terms of amenability to intervention. The researcher will then use the evidence generated to design specific interventions that could improve the reach and impact of campaigns of Zithromax MDA in both countries. While there are contextual differences between nomadic societies throughout Africa, research among the Masai in Tanzania and Kenya should inform programme services in other settings with nomadic populations. Particular attention will be given to gender-sensitivity; that is, interventions that will improve access and use by women as well as men.
Understanding the factors that motivate and sustain community drug distributors in the changing context of NTD control and elimination
How do we motivate community drug distributors (CDDs)?
Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Kenya
- What is the indicator(s) and accompanying M&E strategy that enables country programs to determine when the risk of ongoing transmission of lymphatic filariasis has been reduced so that triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) can be stopped with little risk of resurgence of transmission?
- Can the use of a tailored social mobilization package be used to strengthen community and health system participation and achieve >80% coverage for IDA in Kenya?
Equitable access to Mass Drug Administration for trachoma elimination: an ethnographic study to understand factors associated with low coverage in Kenya and Tanzania
Main objectives are firstly to identify and understand better the factors behind low and unequal MDA coverage and compliance in trachoma endemic areas in Tanzania and Kenya with nomadic populations, secondly to prioritize factors in terms of amenability to intervention. The researcher will then use the evidence generated to design specific interventions that could improve the reach and impact of campaigns of Zithromax MDA in both countries. While there are contextual differences between nomadic societies throughout Africa, research among the Masai in Tanzania and Kenya should inform programme services in other settings with nomadic populations. Particular attention will be given to gender-sensitivity; that is, interventions that will improve access and use by women as well as men.
Sustaining the Gains of NTD elimination programs through focused support of community drug distributors
To sustain the gains of active community drug distributors (CDDs) by enhancing their performance through intervention at the individual, community and primary health care center levels to reach NTD elimination and control goals.